OncLive TV

Michelle E. Melisko, MD, a clinical professor of medicine, University of California, San Francisco (UCSF), discusses the role of neoadjuvant chemotherapy in estrogen receptor (ER)-positive breast cancer.

Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses treatment options for patients with thyroid cancer.

Laura van ’t Veer, PhD, Leader of the Breast Oncology Program, and director of Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the guidelines for genetic testing in breast cancer.

Nadine J. Barrett, PhD, Duke Cancer Institute, discusses the need to address cancer disparities during the Association of Community Cancer Centers (ACCC) 43rd Annual Meeting.

Ashley Rosko, MD, assistant professor in the Division of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment for elderly patients with multiple myeloma.

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the need to develop EAPathways as an improved decision-making tool for oncologists during the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses minimal residual disease (MRD) in hematologic malignancies.

Sibel Blau, MD, medical oncology provider, medical director, Hematology/Oncology, Northwest Medical Specialties, discusses a value-based care model for oncology at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Marco Ruiz, MD, associate physician, Moffitt Cancer Center, discusses HIV-Oncology Clinic at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Alice S. Mims, MD, assistant professor of medicine, Ohio State University Comprehensive Cancer Center, discusses the current challenges with myelofibrosis.

Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the role of entrectinib in treating patients with head and neck cancer.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the role of surgery in kidney cancer.

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses current recommendations for estrogen receptor (ER)-positive breast cancer treatment.

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities associated with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Jerry W. Mitchell, MD, oncologist, Zangmeister Cancer Center, discusses clinical trials exploring medical marijuana for patients with cancer.

Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin lymphoma.

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses treatment for patients with p53-mutated mantle cell lymphoma (MCL).

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.